News
Doing Good in Rebecca's Name
7 February 2019 In Melanoma Stories
It was March of 2005 when Christine Garrison’s life changed forever. She received the phone call that no mother ever wants to receive. Her daughter Rebecca’s suspicious mole was, in fact, Stage 3 melanoma.
When Are Melanoma Patients Finished with Immunotherapy?
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 January 2019 In Melanoma Stories, Science, Treatment
For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? According to Dr. Jeffrey Weber and the data he presented at the European Society for Medical Oncology (ESMO) Congress late last year, the answer is maybe not.
Melanoma Treatment Advances – 2018 in Review
By Marc Hurlbert, PhD, MRA Chief Executive Officer | 18 January 2019 In Science, Treatment
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
From Health Scare to Transformative Change
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 16 January 2019 In Melanoma Stories
Debra Black founded the Melanoma Research Alliance in 2007 after her own diagnosis with Stage II disease earlier that year. Since then, MRA has become the largest, non-profit funder of melanoma research worldwide.
Make Your Sun Safety Habit Stick: La Roche Posay’s My Skin Track UV
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 3 January 2019 In Allies & Partnerships, Prevention
Last month’s arrival of La Roche Posay’s My Skin Track UV may be just what the doctor ordered to help people understand the danger of overexposure to ultraviolet radiation.
MRA Advisor & Grantee Dr. Allison Awarded Nobel Prize for Transforming Cancer Care
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 28 November 2018 In News, Science, Treatment
MRA Scientific Advisory Panel Member & Grantee Dr. Allison Awarded Nobel Prize for his pioneering research to harness the power of the immune system to attack cancer. His work in immunotherapy, which began in the 1990’s, was audacious at the time. It helped to mainstream an entirely new class of tools in the arsenal against cancer; joining the likes of chemotherapy, radiation, and surgery.
Dr. Marc Hurlbert Joins MRA as Chief Science Officer
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 20 November 2018 In Science
Dr. Marc Hurlbert has built his career advancing medical research in support of patients. Now, as of this month, he will translate his skills, relationships, and enthusiasm to achieving our mission of ending death and suffering due to melanoma as MRA’s Chief Science Officer.
When Astrophysics & Melanoma Collide
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 16 November 2018 In Science
Using lessons, processes, and tools from the field of astrophysics, Dr. Taube is studying melanoma in all new ways.
Improving the Lives of Melanoma Survivors
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 15 October 2018 In Prevention, Science
Melanoma survivors are at a 9-fold increased risk of developing another melanoma. Unfortunately, 20% of survivors reported a sunburn in the past year and 10% intentionally went outside for a tan – both strong predictors of inappropriate sun exposure.
Older Patients Do Better on Immunotherapy
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 8 October 2018 In Science, Treatment
In Dr. Weeraratna's study, older patients did better on immunotherapy than younger patients. This surprising result is the opposite of what was expected.